PHARMACEUTICAL COMPOSITION AND DEVICE FOR THE TREATMENT OF PAIN

专利摘要:
the invention relates to a system for intranasal sequential administration of at least one active ingredient belonging to the group of active principles having at least one respiratory depressant side effect DR and at least one active ingredient belonging to the group of active principles counteracting depression. respiratory ADR that can be induced by the active ingredients of the DR group. The invention also relates to a portable intranasal sequential administration device incorporating an intranasal delivery system according to the invention.
公开号:FR3032353A1
申请号:FR1550985
申请日:2015-02-06
公开日:2016-08-12
发明作者:Jacques Seguin；Emad Sabry
申请人:Jacques Seguin；Emad Sabry；
IPC主号:

专利说明:

[0001] The present invention relates to the field of the treatment of pain, and in particular the field of pain treatment based on active principles that may have respiratory depressant side effects.  Among the active ingredients that may have respiratory depressant effects, the invention is specifically directed to the active ingredients opioid agonists and benzodiazepines.  [000]] Opioid agonists are substances whose effects are similar to those of opium, but not chemically related to them.  Opioid agonists exert their action by stimulating opioid receptors.  The formation of the opioid / receptor agonist complex causes a pharmacological response relative to the type of opioid receptor (also called opiate receptor).  [0004] Opioid agonists are used therapeutically for the treatment of pain, or alternatively during substitution treatment during detoxification treatments.  A number of opioid agonists are commonly used, a non-limiting list is given below: alfentanil, apomorphine, buprenorphine, butorphanol, carfentanil, codeine, diamorphine ("heroin"), dextropropoxyphene, dihydromorphine, fentanyl, hydrocodone , hydromorphone, levallorphan, levophenacylmorphan, levorphanol, methadone, morphine, nalbuphine, nalorphine, norlevophanol, oxycodone, oxymorphone, pentazocine, pethidine, propoxyphene, remifentanil, sufentanil, tramadol, etc.  In addition, a number of endogenous substances can be classified as opioid agonists: dynorphins, endomorphins, endorphins, enkephalins, nociceptins.  [0007] Opioid agonists have numerous undesirable side effects: drowsiness, respiratory depression, constipation, nausea / vomiting etc.  Their use must therefore be taken care of most often in the enclosure of the hospital or at least in a medical environment.  The treatment with opioid agonists pose many problems of misuse, because they can serve as a substitute for some hard drugs.  As a result, dispensary supplies require expensive security systems.  Finally, rapid habituation to this type of treatment associated with long duration of treatment may result in an increase in doses likely to make the patient dependent, especially when the administration is "on demand".  Consequently, a therapy based on opioid agonist 3032353 2 requires strict supervision and a strong involvement of medical personnel, which is problematic in a context of cost optimization.  [0009] There are three main types of opioid receptors, these are mu (p), delta (6) and kappa (k) receptors widely distributed in the brain and in certain peripheral zones.  [00010] The opioid antagonists, unlike opioid agonists, are characterized by an inhibitory activity of at least one opioid receptor.  They can be divided into two main classes: specific opioid antagonists (of some opioid receptors only) and non-specific opioid antagonists.  Non-specific opioid antagonists include naloxone, naltrexone and nalmefene.  [00011] Opioid agonists may be associated with opioid antagonists, in the case of opioid intoxication or even to limit certain side effects.  [00012] For the administration of opioids, injectable solutions are nowadays very largely used, especially in hospital environments.  This route of administration has a number of advantages, in particular the effect is very rapid and the bioavailability is fairly well controlled, which does not prevent it from being imperfect.  Indeed, in addition to the discomfort of the injection and the need for the intervention of a professional, some side effects are very pronounced, for example, to name only one, respiratory depression.  Benzodiazepines are mainly used for their main properties: hypnotics, anxiolytics, antiepileptics, amnesic and muscle relaxants.  A number of benzodiazepines are commonly used, a nonlimiting list is given below: alprazolam, bromazepam, chlordiazepoxide, clobazam, clonazepam, clotiazepam, clorazepate, diazepam, estazolam, flunitrazepam, loprazolam, lorazepam, lormetazepam, midazolam, nitrazepam, nordazepam, oxazepam, prazepam, temazepam, tetrazepam, triazolam, etc.  [00015] Benzodiazepines have numerous undesirable side effects: amnesia, behavioral disorders, tolerance, respiratory depression, etc.  The benzodiazepine antagonists, unlike benzodiazepines, are characterized by an inhibitory activity of benzodiazepine activity.  The best known is flumazenil.  Benzodiazepines may be associated with a benzodiazepine antagonist, in the case of benzodiazepine intoxication or even to limit certain side effects, including respiratory depression.  The "pickle" agonists and benzodiazepines therefore belong to the DR group of active ingredients having at least one respiratory depressant side effect.  The opioid antagonists and the benzodiazepine antagonists belong to the ADR group of active ingredients that counteract respiratory depression.  In the present application, it is made use of certain terms and expressions, their definitions being presented below.  "Active formulation": a formulation comprising one or more pharmaceutical active principle (s).  The active principle (s) may be formulated as a non-molecular solution or dispersion.  The active principle (s) may also be formulated in a form modifying its (their) properties, in particular those related to membrane passage and bioavailability; microcapsules, liposomes, fast-acting forms, etc.  "Intranasal administration": administration of active principle (s) in the patient's nasal cavity, the active ingredient (s) may be in different forms: gas, vapor, microdroplets, powder in suspension, etc.  Intranasal administration is also characterized by the fact that most of the active principle (s) absorbed by the patient is at the level of the nasal mucosa.  [00023] "Sequential Administration": administration composed of several successive administrations.  "Respiratory depressant effect": effect following the administration of one or more active principle (s), may be manifested by the appearance of one or more signs (s) of respiratory depression: hypoxia tissue, increased levels of carbon dioxide in the exhaled air, decreased oxygen levels in exhaled air, decreased respiratory rate, decreased breathing amplitude, etc.  "Undesirable side effect" effect of an active ingredient which is characterized by the fact that it is not directly desired.  The limitation of the effect can be achieved by administering a certain amount of an active ingredient countering the undesirable side effect.  [00026] "Administration autonomously": administration performed by and for the patient himself.  When the administration takes place in the animal, it is understood that the administration is carried out by the breeder.  [00027] "Energy source": this is an autonomous energy source, which can be useful to allow the administration autonomously as indicated above.  It is generally portable, and preferably integrated into a portable intranasal delivery system or device.  For example a battery, a battery, a source of photovoltaic energy, energy recovered from the patient for example by means of motion capture or heat, etc.  [00028] "Administration outside any nedicated structure *: a sequence composed of several successive administrations can take place without any control of a health professional.  Optionally, therapy may be advocated, in accordance with the reference legislation, by a health professional, but the administration itself may take place in places where such professionals are neither present nor necessary.  "Initial stage": time period during which the first administration of the therapy is performed.  "Subsequent stage (s)": time period (s) during which all the administrations other than the first administration of the therapy are carried out.  [00031] "Simultaneous administration / simultaneous administration": administration at the same time of at least two active principles.  In a variant, each of the active ingredients is administered such that their pharmacological actions begin at the same time and / or are globally simultaneous.  In another variant, the active ingredients are formulated in the form of a mixture.  [00032] "Choice of administration": decision-making having the effect, when the patient wishes to perform an administration, to issue him or that active formulation according to said decision.  [00033] "Intelligence medium": element whose function is to acquire and transmit information for decision making and therefore a choice of administration.  It can be a time counting means, or even a device for measuring at least one biological parameter.  [00034] "time counting means": any means for measuring time intervals.  This may include a clock, a stopwatch, a countdown timer, a microprocessor operating at a known operating frequency, etc.  "Biological parameter": biological characteristic of the patient, in the form of an encrypted or quantifiable value.  It may for example be the oxygen saturation, or even the respiratory rate.  [000] 6] "Device for measuring at least one biological parameter": device whose function is the production of a numerical value corresponding to a biological parameter of the patient.  "Device for measuring at least one biological parameter introduced concomitantly": device of which at least a portion is located in the nasal cavity for at least the beginning of the administration step.  3032353 [00038] "Patient signal device": device emitting a signal perceptible by the patient to obtain information on the choice of administration in case of activation of the control means.  The signal may for example consist of a light signal.  When the signal is positive, it means that an active formulation "DR active ingredient with or without active ingredient ADR" can be issued to it.  When the signal is negative, it means that an active formulation does not comprise active ingredient DR but comprising active ingredient ADR can be delivered to it.  In summary, when at least one means of information transmits information to the signal processing unit opposing the linking of the active formulation "active ingredient DR with or without active ingredient ADR" and the distribution means , then the patient signal device emits a negative signal to the patient.  "Sprayable liquid": liquid capable of being converted into droplets and / or microdroplets.  [00040] "Mixture of active ingredients": presence of active ingredients within the same storage space.  The mixture can be in liquid, solid or gaseous form.  In the case of a liquid or gaseous mixture, the molecules of the different active ingredients can be dispersed within the same storage space, which is called a molecular mixture.  "Opioid Agonist": active ingredient that acts on at least one opioid receptor similarly to opium.  [00042] "Opioid antagonist": active ingredient that acts on at least one opioid receptor oppositely to opium.  "Initial actuation of the system": first actuation of the administration system of the therapy, performed by the patient wishing to receive an initial administration.  There can be only one initial actuation of the system during the same therapy.  [00044] "Later activation of the system": subsequent actuation of the administration system of the therapy, performed by the patient wishing to receive an administration.  There may be one or more actuation (s) of the system during the same therapy.  [000451 "Portable intranasal administration device": device that can be transported by the patient, and not constituting a load that can truly limit its mobility.  In particular, the device can be so easily transportable that a simple event of having to resort to it, for example in an emergency situation, can justify its integration into individual equipment.  It can in particular be arranged in a pocket, a hand, a bag, a car glove box, a handbag, a capsule resistant to water and / or sand, etc.  3032353 6 [00046] "Storage space": confined space containing an active formulation.  In the confined space, atmospheric exchanges with the outside are weak or non-existent, and can not, in the short term, cause a qualitative and / or quantitative change in the formulation.  When using the device, this space can be brought to communicate.  with the outside.  "Connecting means": set of elements for communicating the storage space and the distribution means.  It may in particular be a mechanical barrier, for example a valve.  [000481 "Signal Processing Unit": an entity connected both to the intelligence means and to the linking means.  The intelligence means transmit information to it that is evaluated by the signal processing unit, the operation of which is configured or programmed to enable it to transmit one or more operation control signals to the connection means. , depending on the assessments made.  [00049] "Excessive respiratory depression": state of respiratory depression such as the benefit / risk ratio of the simultaneous administration of at least one active ingredient from the ADR group and at least one active ingredient from the DR group n ' is not desirable.  For example, when the measured biological parameter is oxygen saturation, the respiratory depression may be considered excessive when the oxygen saturation value is less than 85%.  For example, when the biological parameter is the respiratory rate, the respiratory depression may be considered excessive when the value of the respiratory rate is less than 12 inhalation / expiration cycles per minute.  [00050] "Removable storage spaces": storage spaces that can be removed from the device without rendering it permanently unusable.  [00051] "Interchangeable storage spaces": storage spaces that can be acquired, according to the regulations in force, regardless of the device.  "Means of distribution of active formulations suitable for transmission through the nasal mucosa": element or set of elements for putting active formulations in contact with the nasal mucosa.  [00053] "Power supply source": supply of electrical power to the portable device.  This electric current can be generated by a battery, a battery, a capacitor, a means of collecting solar energy, a means of collecting the energy of the patient (mechanical energy, body heat, etc.). ).  Despite the strong need for therapy based on analgesic active ingredients such as oRioïd agonists or benzodiazepines, their interest is limited by their side effects, and in particular by respiratory depression.  In the future, these therapies will have to present a certain number of improvements, and this from several points of view: from the point of view of the ergonomics of the treatment: secure administration, facilitated catches, non-invasive administration, limitation of post-treatment addiction, etc.  - from the financial point of view: limitation of the intervention of the nursing staff, shorter or no hospital stays, reduction of the misuse having an impact on the health systems, reduction of the costs of the distribution networks, etc.  ; - from the point of view of public health: reduction of respiratory depression, limited misuse, etc.  In particular, there is a need felt for a long time to be able to have a technical solution for administering, in a controlled manner, but independently, and outside any medicalized structure, by the patient himself principles active agents used in the treatment of pain while at the same time managing the undesirable side effects following such treatment.  This need is very pronounced for people who are far from any treatment center, hospital, clinic, health center, infirmary, etc.  or far from any medical personnel, such as soldiers, journalists, adventurers, explorers, hunters, hikers, mountaineers.  Indeed, they are often found in places where the objective dangers involving the maintenance of bodily integrity are quite significant, and the risk of inflicting themselves or being inflicted, traumatic wounds is quite high.  These people therefore need a simple therapeutic solution allowing them to handle all kinds of situations where there is a manifestation of pain by an adequate administration of appropriate products, and at the same time to avoid succumbing to, or suffering secondary side effects of these same products.  [00056] Various teams have worked in particular on improvements in opioid treatment, but without obtaining satisfactory results.  In the Chinese application CN 102068697, the inventor combines an opioid agonist and an opioid antagonist, in order to allegedly limit the adverse effects of the opioid agonist without, however, impact its effect.  A nasal spray comprising a fentanyl / naltrexone mixture is contemplated.  No device to limit the number of doses is described, nor any means to control the potential side effects once the metabolized agonist.  [00058] In the application US 2007 / 186,923 in the name of AceIRx Pharmaceuticals, the inventor proposes a medical device of administration that can be used for the administration of opioid agonists in the oral mucosa.  A safety device guarantees a spill of opioid antagonist when attempting to recover the opioid agonist solution.  It is therefore a safety system ensuring the neutralization of the effect of the opioid agonist composition in case of diversion attempt, making this composition unusable.  Under normal conditions of use, no mixing is performed between the opioid agonist and the opioid antagonist, and no antagonist administration takes place.  In the application WO 2012/024,106 in the name of UNIVERSITY OF FLORIDA is described a complex system consisting of acquisition of pharmacokinetic and pharmacodynamic data, algorithmic analysis, then a response that can be of several kinds.  It is specified that the oximeter is not considered as a reliable device for detecting abnormality, other probes are preferred.  In addition, the device does not appear transportable.  In the application WO 96/40332 in the name of GO MEDICAL, a medical device for intranasal administration of opioid agonist is described.  No incorporation of antagonist is envisaged, the medical device comprises an opioid agonist solution, as well as other active molecules other than opioid antagonists.  Finally, no device for limiting misuse is described, but only a catch control system for a patient of "good faith", that is to say not wanting to divert the compositions.  The US patent published under number US4464378 relates to methods of intranasal administration of opioid antagonists or agonists and to the corresponding administration formulations, especially in gel form.  The objective expressed in this patent was to circumvent the difficulties encountered with the use of certain known products which had insufficient oral bioavailability.  Applicants of this patent have therefore sought to formulate solutions, gels, suspensions and ointments containing the opioid agonist or antagonist alone for intranasal administration.  [00062] In another approach, US Patent Publication No. US5629011 relates to intranasal formulations of polar metabolites of opioid agonists in combination with an absorption promoter acting at the level of the mucous membranes.  US Patent No. US5767215 discloses a method of co-administering an opioid agonist with an opioid antagonist.  The agonist is selected from morphine, codeine, fentanyl analogues, pentazocine, buprenorphine, methadone, enkephalins, dynorphins and endorphins, and opioid alkaloids and peptides that behave in the same way.  The antagonists are selected from naltrexone, naloxone, etorphine, diprenorphine, dihydroetorphine, and opioid alkaloids and peptides behaving in the same manner.  The products are administered to mice by intraperitoneal injection, but mention is made of the possibility of preparing formulations for oral, sublingual, intravenous, intramuscular, subcutaneous, or transdermal administration.  [00064] The PCT patent application published under the number WO 01/58447 relates to compositions containing an opioid agonist and an opioid antagonist which can be formulated for intranasal administration.  It should be noted that the opioid antagonist here is embedded in a substrate, for example a polysaccharide, to form microspheres to control its release on the mucous membranes so as to guarantee the effect of the antagonist during the effect. of the agonist.  [00065] In the field of intranasal delivery systems and devices, there is also known the US patent published under the number US6948492 whose objective is to protect a method of control of the minimum time between the self-administration of a plurality of unit doses of an intranasal pharmaceutical composition of opiates by a patient capable of self-administering said composition.  The unit doses contained in vials are deposited on a star support around a hub that can rotate to advance the unit dose after each use, but only after a certain predetermined period of time has elapsed.  The star support is constantly skewed to rotate and advance the bottles, but its progression is retained by a metal spring and a shape memory alloy wire, whose blocking is controlled by a microprocessor that performs the counting between each administration.  This is not a question of co-administration of an opioid agonist and antagonist, or of any other form of control preventing the inappropriate administration of the composition.  Indeed, it remains possible with this device to self-administer subsequent doses of opiate composition without being in a physiological state to support such administration.  In summary, none of the solutions mentioned above solves all three aspects mentioned.  As will be explained below, the device according to the invention solves the problems mentioned above.  The present invention relates to uses, systems and devices incorporating such systems, as well as methods of administration, in the management of pain.  The different objects according to the invention will become apparent through the following description.  The implementation of the present will have the following advantages: - concerning the ergonomics of the treatment: secure administration, facilitated catches, non-invasive administration, limitation of post-treatment dependence, etc.  ; - concerning the financial aspect: a limitation of the intervention of the nursing staff, reduced hospitalization times, a reduction of misuse having an impact on the health systems, a reduction of the costs of supply chain, etc.  ; - from the point of view of public health: a reduction of respiratory depression, limited misuse, etc.  The present invention also relates to uses, systems and devices incorporating such systems, as well as methods of administration in the management of pain in animals.  In the latter case, it is understood that the administration is carried out by the master / breeder and not by the patient / subject, the latter being the animal.  The present invention firstly relates to a method of intranasal sequential administration of at least one active ingredient belonging to the group of active ingredients having at least one respiratory depressant side effect DR and at least one active ingredient belonging to the group of active principles controlling respiratory depression ADR that can be induced by the active principles of the DR group, intended to be implemented by the patient himself independently and outside any medical structure comprising: - an initial step of intranasal administration of at least one active ingredient from the DR group, and at least one subsequent step of intranasal administration of at least one active ingredient from the ADR group alone or from at least one active ingredient from the DR group, the choice of the administration of the said at least one subsequent step being slaved to one or more means of intelligence.  In one embodiment, the intranasal sequential administration method comprises: an initial step of intranasal administration of at least one active ingredient from the DR group and from at least one active ingredient from the ADR group, and at least one subsequent stage of intranasal administration of at least one active principle originating from the ADR group alone or from at least one active ingredient from the DR group and from at least one active ingredient ir from the ADR group simultaneous, the choice of the administration of said at least one subsequent step being slaved to one or more means (s) intelligence.  When the at least one active ingredient from the DR group is an opioid (and the at least one active ingredient from the ADR group is therefore an active ingredient counteracting opioid-induced respiratory depression, such as by naloxone), then generally it will be expected that when the opioid of the DR group is administered, then it is with an active ingredient of the ADR group such as naloxone, simultaneously.  Conversely, when the at least one active ingredient from the DR group is a benzodiazepine (and that the at least one active ingredient from the ADR group is an active ingredient counteracting respiratory depression induced by benzodiazepines such as flumazenil), then generally it will be expected that when the benzodiazepine of the DR group is administered, then it is alone, without active ingredient of the group ADR.  In one embodiment, the intranasal sequential administration method comprises: an initial step, intranasal administration of at least one active ingredient from the DR group and at least one subsequent intranasal administration step; at least one active ingredient from the ADR group alone, the choice of administration of said subsequent step being slaved to one or more means of intelligence.  In one embodiment, the intranasal sequential administration method comprises: an initial step, intranasal administration of at least one active ingredient derived from the DR group and at least one subsequent intranasal administration step; at least one active ingredient from the DR group and from at least one active ingredient from the ADR group simultaneously, the choice of administration of said subsequent step being slaved to one or more means of intelligence.  In one embodiment, the intranasal sequential administration method comprises: an initial step, of intranasal administration of at least one active ingredient from the DR group and from at least one active ingredient from the ADR group and at least one subsequent step of intranasal administration of at least one active ingredient from the ADR group alone, the choice of administration of said subsequent step being slaved to one or more means of intelligence.  In one embodiment, the intranasal sequential administration method comprises: an initial step, of intranasal administration of at least one active ingredient from the DR group and from at least one active ingredient from the ADR group and at least one subsequent step of intranasal administration of at least one active ingredient from the DR group and at least one active ingredient from the ADR group simultaneously, the choice of administration of said subsequent step being subject to one or more means of information.  In one embodiment, the initial step is also slaved to one or more means (s) intelligence.  In one embodiment, the intelligence means are at least one device for measuring at least one biological parameter and / or a time counting means.  In one embodiment, the intelligence means are at least one device for measuring at least one biological parameter and a time counting means.  In one embodiment, the intelligence means are at least one oximeter and / or a respiratory rate sensor and / or a time counting means.  In one embodiment, the intelligence means are at least one oximeter and a respiratory rate sensor and a time counting means.  In one embodiment: when the time counting means indicates an interval of administration less than a threshold value, the subsequent intranasal administration step consists in the administration of at least one principle active from the group ADR AND / OR - when at least one device for measuring at least one biological parameter indicates an excessive respiratory depression the subsequent stage of intranasal administration consists in the administration of at least one active principle derived from ADR group; AND in all other cases, the subsequent intranasal administration step consists of the administration of at least one active ingredient from the DR group.  In one embodiment: when the time counting means indicates an interval of administration lower than a threshold value, the subsequent intranasal administration step consists in the administration of at least one active principle derived from the ADR group; And / or 3032353 13 - when at least one device for measuring at least one biological parameter signals an excessive respiratory depression, the subsequent intranasal administration step consists of the administration of at least one active ingredient from the ADR group; AND in all other cases, the subsequent intranasal administration step consists in the administration of at least one active ingredient from the DR group and from at least one active ingredient from the ADR group simultaneously.  The present invention also relates to at least one active ingredient belonging to the group of active principles having at least one respiratory depressant side effect DR and at least one active ingredient belonging to the group of active ingredients that counteract the respiratory depression ADR that can be induced by the active ingredients of the DR group, for their use in the treatment of pain, said use being characterized in that their intranasal sequential administration intended to be carried out by the patient himself independently and outside any medical structure comprises an initial stage of intranasal administration of at least one active ingredient from the DR group and at least one subsequent stage of intranasal administration of at least one active ingredient from the ADR group alone or from at least one active principle from the DR group, the choice of the administration of said at least one subsequent step being sufficient rvi to one or more means of information.  In one embodiment, the intranasal sequential administration intended to be carried out by the patient himself autonomously and outside any medicalized structure comprises: an initial intranasal administration step of at least an active principle derived from the DR group and from at least one active ingredient from the ADR group, and - at least one subsequent intranasal administration step is at least one active ingredient from the ADR group alone or at least one active ingredient from the DR group and at least one active ingredient from the group ADR simultaneously, the choice of the administration of said at least one subsequent step being slaved to one or more means (s) intelligence.  When the at least one active ingredient from the DR group is an opioid (and that the at least one active ingredient from the ADR group is an active ingredient counteracting the opioid-induced respiratory depression such as naloxone, for example ), then generally it will be expected that when the opioid of the DR group is administered, then it is with an active ingredient of the ADR group such as naloxone, simultaneously.  Conversely, when the at least one active ingredient from the DR group is a benzodiazepine (and the at least one active ingredient from the ADR group is therefore an active ingredient counteracting respiratory depression induced by benzodiazepines such as flumazenil), then generally it will be expected that when the benzodiazepine of the DR group is administered, then it is alone, without active ingredient of the group ADR.  In one embodiment, the intranasal sequential administration intended to be carried out by the patient himself independently and outside of any medical structure comprises: an initial stage of intranasal administration of least one active ingredient from the DR group and at least one subsequent step of intranasal administration of at least one active ingredient from the ADR group alone, the choice of administration of said subsequent step being slaved to one or more means ( s) intelligence.  In one embodiment, the intranasal sequential administration intended to be carried out by the patient himself independently and outside of any medicalized structure comprises: an initial stage of intranasal administration of least one active principle from the DR group and and at least one subsequent step of intranasal administration of at least one active ingredient from the DR group, the choice of administration of said subsequent step being controlled by one or more means ( s) intelligence.  In one embodiment, the intranasal sequential administration intended to be carried out by the patient himself independently and outside of any medicalized structure comprises: an initial stage of intranasal administration of least one active ingredient from the DR group and from at least one active ingredient from the ADR group, and at least one subsequent step of intranasal administration of at least one active ingredient from the ADR group alone, the choice of the administration of said subsequent step being slaved to one or more means of intelligence.  In one embodiment, the intranasal sequential administration intended to be carried out by the patient himself independently and outside of any medicalized structure comprises: an initial stage of intranasal administration of at least one active ingredient derived from the DR group and at least one active ingredient from the ADR group, and 3032353 - at least one subsequent step of intranasal administration of at least one active ingredient from the DR group and from at least one least one active ingredient from the ADR group simultaneously, the choice of administration of said subsequent step being slaved to one or more means (s) intelligence.  In one embodiment, the initial step is also slaved to one or more means of intelligence In one embodiment, the intelligence means are at least one measuring device of at least one a biological parameter and / or a time counting means.  In one embodiment, the intelligence means are at least one device for measuring at least one biological parameter and a time counting means.  In one embodiment, the intelligence means are at least one oximeter and / or a respiratory rate sensor and / or a time counting means.  In one embodiment, the intelligence means are at least one oximeter and a respiratory rate sensor and a time counting means.  In one embodiment: when the time counting means indicates an interval of administration less than a threshold value, the subsequent intranasal administration step consists of the administration of at least one active ingredient derived from the ADR group; AND / OR when at least one device for measuring at least one biological parameter indicates an excessive respiratory depression, the subsequent stage of intranasal administration consists of the administration of at least one active ingredient from the ADR group; AND - in all other cases, the subsequent stage of intranasal administration consists of the administration of at least one active ingredient from the DR group.  In one embodiment: when the time-counting means indicates an interval of administration lower than a threshold value, the subsequent intranasal administration step consists in the administration of at least one active principle derived from the ADR group; When at least one device for measuring at least one biological parameter indicates an excessive respiratory depression, the subsequent stage of intranasal administration consists of the administration of at least one active ingredient from the ADR group; AND in all other cases, the subsequent intranasal administration step consists in the administration of at least one active ingredient from the DR group and from at least one active ingredient from the ADR group simultaneously.  [000101] The invention also relates to an intranasal sequential delivery system.  This administration system can be particularly useful for isolated people, in situations similar to those mentioned above.  In particular, the invention relates to an intranasal sequential administration system of at least one active ingredient belonging to the group of active principles having at least one respiratory depressant side effect DR and at least one active ingredient belonging to the group. active principles controlling the ADR respiratory depression that can be induced by the active principles of the DR group, which system comprises: (a) the simultaneous administration of at least one active ingredient from the DR group, in response to an initial actuation of the DR group; system performed by a subject desiring to receive the pharmaceutical administration, said administration constituting an initial administration registered by the system; (b) at least one administration subsequent to the initial administration, either of at least one active ingredient from the ADR group, or of at least one active ingredient from the DR group, in response to at least one subsequent actuation of the system performed by a subject desiring to receive subsequent pharmaceutical administration, which administration constitutes a subsequent event recorded by the system; - the choice of the subsequent administration being enslaved to one or more means of intelligence.  In one embodiment, the system comprises: (a) the simultaneous administration of at least one active ingredient from the DR group and from at least one active ingredient from the ADR group, in response to an actuation initial system performed by a subject desiring to receive pharmaceutical administration, this administration constituting an initial administration recorded by the system; And (b) at least one administration subsequent to the initial administration, that is to say at least one active ingredient from the ADR group, or at least one active ingredient from the DR group and from at least one active principle. from the ADR group simultaneously, in response to at least one subsequent actuation of the system performed by a subsequent pharmaceutical desiring subject, this subsequent administration recorded by the system; [000105] the choice of the subsequent administration being means (s) intelligence.  When the at least one active ingredient from the DR group is an opioid (and the at least one active principle from the ADR group is an active ingredient counteracting opioid-induced respiratory depression such as naloxone ), then generally it will be expected that when the opioid of the DR group is administered, then it is with an active ingredient of the ADR group such as naloxone, simultaneously.  Conversely, when the at least one active ingredient from the DR group is a benzodiazepine (and the at least one active ingredient from the ADR group is therefore an active ingredient counteracting respiratory depression induced by benzodiazepines, for example flumazenil), then generally it will be expected that when the benzodiazepine of the DR group is administered, then it is alone, without active ingredient of the group ADR.  In one embodiment, the system comprises - an initial intranasal administration of at least one DR group and - at least one subsequent intranasal administration of at least one active ingredient from the ADR group alone, [000109] the choice of the subsequent administration being enslaved means (s) of intelligence.  In one embodiment, the system comprises: an initial intranasal administration of at least one active ingredient derived from the DR group and at least one subsequent intranasal administration of at least one active ingredient from the DR group; 000111] the choice of the administration of said subsequent step being slaved to one or more means of information.  In one embodiment, the system comprises: - an initial intranasal administration of at least one of at least one active ingredient derived from the initial administration or several times to an initial administration; an active principle derived from the DR group and from at least one active principle derived from the ADR group, and - at least one intranasal administration subsequent to the initial administration of at least one active principle originating from the ADR group alone, [000113] the choice of the subsequent administration being dependent on one or more means of intelligence.  In one embodiment, the system comprises: an initial intranasal administration of at least one active principle derived from the DR group and from at least one active principle derived from the ADR group, and at least one subsequent intranasal administration. of at least one active ingredient from the DR group and from at least one active ingredient from the ADR group simultaneously, the choice of the administration of said subsequent step being slaved to one or more means (s) information.  In one embodiment, the administration (a) is also slaved to one or more means (s) of intelligence comprising at least the measurement of a biological parameter.  In one embodiment, the intelligence means are at least one device for measuring at least one biological parameter and / or a time counting means.  In one embodiment, the intelligence means are at least one device for measuring at least one biological parameter and a time counting means.  In one embodiment, the intelligence means are at least one oximeter and / or a respiratory rate sensor and / or a time counting means.  In one embodiment, the intelligence means are at least one oximeter and a respiratory rate sensor and a time counting means.  In one embodiment: when the timer indicates a lower administration interval than a threshold value, then the subsequent administration consists of the administration of at least one active ingredient from the ADR group; AND / OR - when at least one device for measuring at least one biological parameter indicates an excessive respiratory depression, then the subsequent administration consists of the administration of at least one active ingredient from the ADR group; And in all other cases, the subsequent administration consists of the administration of at least one active ingredient from the DR group.  In one embodiment: when the timer indicates a lower threshold value of administration interval, then the subsequent administration consists of the administration of at least one active ingredient from the ADR group; AND / OR - when at least one device for measuring at least one biological parameter indicates an excessive respiratory depression, then the subsequent administration consists of the administration of at least one active ingredient from the ADR group; AND in all other cases, the subsequent administration consists of the administration of at least one active ingredient from the DR group and from at least one active ingredient from the ADR group simultaneously.  The invention also relates to a portable intranasal sequential administration device incorporating an intranasal delivery system according to the invention.  The device according to the invention will be better understood on reading the description of the figures, which follows.  Figure 1: Example of Device According to the Invention [000125] Figure 1 illustrates a portable intranasal delivery device 1 according to the invention.  A first storage space 2 contains a first active formulation 12 comprising an active ingredient from the group DR 12a and an active ingredient from the group ADR 12b.  A second storage space] contains a second active formulation 11 comprising at least one active ingredient from the group ADR 11a.  The signal processing unit 4 is connected on the one hand to the connecting means 5, said connecting means comprising a management chamber 5m, a valve Sc, a valve axis 5b as well as ducts 5d, 5e, connected to the respective storage spaces 2,].  The signal processing unit 4 is also connected to the intelligence means 6 comprising an oximeter 6c, a respiratory rate sensor 6b and a clock 6a.  When using the device 1, the user introduces the nasal nozzle 7a in the nasal cavity (not shown).  The information means, here in the example the oximeter 6c, the frequency sensor 6b, can measure or determine values 3032353 and communicate them to the signal processing unit 4.  This also communicates with the clock 6a, to calculate the lapse of time since the last active formulation administration 12.  Alternatively, the signal processing unit 4 can integrate a clock, for example a PSTN circuit, or other time counter, thus avoiding providing a separate clock.  When the user activates the control means 8, in the present example represented by a push button 8a, the signal processing unit 4, according to the information transmitted by the intelligence means 6, controls the setting in relation via the connecting means 5 or the first storage space 2 with the dispensing means 7, or the second storage space] with the dispensing means 7, for example, a nosepiece 7a, and more specifically with the distribution duct 5f.  In the figure shown, the connection comprises the actuation of a valve 5b, mounted on an axis 5b inside the administration chamber 5a, which switches on both sides of the rotation axis 5b to be pressed against a side wall of the chamber and thus close one of the ducts 5d, 5e, depending on the product to be administered, as determined by the signal processing unit 4.  [0001] 0] The selected formulation, to be put in relation with the outside then circulates in the distribution duct 5f, exits through the outlet 13 and is placed in contact with the nasal mucosa.  At any time, the user can obtain information on the administration formulation in case of activation of the push button 6a via the patient signal means 9, for example, a light indicator 9a.  It may then decide on the activation or not of the push button 6a.  An autonomous power source 10 supplies the entire device, for example a rechargeable battery or not, or photovoltaic cells, or any other suitable source.  Figure 2: block diagram of a device according to the invention [000134] Figure 2 shows a block diagram of a device 1 according to the invention.  It can be seen that the signal processing unit 4 is connected to: the intelligence means 6; connecting means 5; the control means 8; to the indicator light 9a.  The linking means are connected to the storage spaces 2 and 3; to the distribution means 7.  [0001] When using the device 1, the intelligence means communicate information to the signal processing unit 4.  [000138] When the user activates the control means 8, the signal processing unit 4, according to the information transmitted by the intelligence means 6, controls the connection via the connection means 5 of the first storage space 2 with the distribution means 7, or the second storage space 3 with the distribution means 7.  An autonomous power source 10 supplies the entire device, for example a rechargeable battery or not, or photovoltaic cells, or any other appropriate source.  The medical device 1 according to the invention is intended to be used by the patient wishing to perform a therapy.  It is likely to be used by isolated people, who are in situations as mentioned above.  To use it, the patient will have to take it out quickly from his equipment (for example a backpack), as well as from his case.  Then he will have to position the dispensing means 7, which may be for example a nosepiece 7a.  In some cases, it will refer to the patient signal device 9 (which may be for example a light signal 9a), in order to know which of the two formulations would be administered to it in case of activation of the control means 8.  Finally, it will only have to activate the control means 8, which may be for example a push button 8a, any other type of device intended to receive mechanical stress, or else a device that can be activated by the patient's voice, etc. .  Without the need to think too much, the patient can, through the device, thus perform an administration.  The patient can, as part of his therapy, achieve as much administration as he wants.  This therapy will be a therapy "on demand" but totally secure and therefore without risk.  [000141] The medical device incorporates several active formulations 11 and 12 whose qualitative and quantitative compositions can be adapted to a given patient.  The choice of this or that dosage, as well as the use of such active principle (s), may be at the discretion of the medical staff.  The duration of the time counting means that can be for example a clock 6a (minimum duration between two "DR active ingredient / ADR active principle") can be set in advance by the medical staff.  The medical device 1 will thus be able to simplify delicate situations, particularly in the context of use in times of armed conflict.  In one embodiment, the intranasal sequential administration device 1 incorporating an intranasal delivery system according to the invention comprises: a first storage space 2 containing a first sprayable active formulation comprising at least one active ingredient from DR 12a group; a second storage space comprising a second sprayable active formulation 11 different from the first active formulation and comprising at least one active ingredient derived from the ADR group 11a; a signal processing unit 4; means for linking the first 12 and second 11 active formulations of said first 2 and second 3 respective storage spaces with the distribution means 7, operatively connected to the signal processing unit 4; one or more intelligence means 6, operatively connected to the signal processing unit 4; control means 8 enabling the subject receiving said active formulations to perform self-administration of said active formulations outside any medical facility; distribution means 7 of the active formulations adapted for transmission through the nasal mucosa; and an autonomous power source 10, the signal processing unit 4, the connection means 5, the intelligence means (s) 6 and the control means 8 being configured to enable, in function of one or more signals received by the signal processing unit 4 from the intelligence medium (s) 6, ie the linking of the first active formulation 12 of the first storage space 2 to the distribution means 7, ie the linking of the second active formulation 11 of the second storage space 3 to the distribution means 7.  In one embodiment, the intranasal sequential administration device 1 incorporating an intranasal delivery system according to the invention comprises: a first storage space 2 containing a first sprayable active formulation comprising at least one principle active ingredient from the group DR 12a and at least one active ingredient from the group ADR 12b; A second storage space 3 comprising a second sprayable active formulation 11 different from the first active formulation and comprising at least one active ingredient from the ADR group 11a; a signal processing unit 4; means for linking the first 12 and second 11 active formulations of said first 2 and second 3 respective storage spaces with the distribution means 7, operatively connected to the signal processing unit 4; one or more intelligence means 6, operatively connected to the signal processing unit 4; control means 8 enabling the subject receiving said active formulations to perform self-administration of said active formulations outside any medical facility; distribution means 7 of the active formulations adapted for transmission through the nasal mucosa; and an autonomous power source 10, the signal processing unit 4, the connection means 5, the intelligence means (s) 6 and the control means 8 being configured to enable, in function of one or more signals received by the signal processing unit 4 from the intelligence node (s) 6, that is to say the linking of the first active formulation 12 of the first storage space 2 to the distribution means 7, ie the linking of the second active formulation 11 of the second storage space 3 to the distribution means 7.  When the at least one active ingredient from the DR group is an opioid (and the at least one active ingredient from the ADR group is an active ingredient counteracting opioid-induced respiratory depression such as naloxone, for example). ), then generally it will be expected that the first storage space 2 comprising the first active formulation 12 comprises both an active ingredient from the group DR selected from opioids and an active ingredient from the group ADR, which may be for example the naloxone.  Conversely, when the at least one active ingredient from the DR group is a benzodiazepine (and that the at least one active principle from the ADR group is an active ingredient counteracting respiratory depression induced by benzodiazepines, for example flumazenil), then generally it will be expected that the first storage space 2 comprising the first active formulation 12 comprises an active ingredient from the DR group selected from benzodiazepines but no active ingredient from the ADR group.  In one embodiment, the energy source 10 is electric.  [000148] In one embodiment, the signal processing unit 4 comprises a microprocessor.  In one embodiment, the signal processing unit 4 is operatively connected to one or more memory areas for storing data received from the intelligence means (s) 6.  [000150] In one embodiment, the intelligence means 6 are at least one device for measuring at least one biological parameter and / or a time counting means.  In one embodiment, the intelligence means 6 are at least one device for measuring at least one biological parameter and a time counting means.  In one embodiment, the intelligence means 6 are at least one oximeter 6c and / or a respiratory rate sensor 6b and / or a time counting means.  In one embodiment, the intelligence means 6 are at least one oxygen sensor 6c and a respiratory frequency sensor 6b and a time counting means.  In one embodiment, the dispensing means 7 of the active formulations is a nosepiece 7a, and the oximeter 6c and the respiratory rate sensor 6b are located on said nosepiece 6a, for measuring or calculating a physiological value. obtained from the subject to receive the administration of said active formulations.  In one embodiment, the time counting means is integrated in the microprocessor of the signal processing unit 4.  In one embodiment: the device (s) for measuring at least one biological parameter is (are) and / or calculates (a) a biological parameter, and sends (s) information to the signal processing unit 4 for storing a physiological result value in a memory area; the signal processing unit 4, when receiving the information coming from the device for measuring at least one biological parameter, interrogates the time counting means to obtain a current time value and store it in memory area.  [000157] In one embodiment: the signal processing unit 4 compares a physiological result value obtained from the device (s) for measuring at least one biological parameter with a value Stored threshold in a memory area; 3032353 - the signal processing unit 4 compares the time value stored in the memory area with an updated time value received from the time counting means at the time of the comparison to calculate an elapsed time interval since the previous administration; according to the determination of these comparisons, the signal processing unit 4 sends a signal to the connecting means 5 to enable the subject to receive the administration to actuate the control means 8 and to allow administer one of the active formulations.  [000158] In one embodiment: if the signal processing unit 4 determines that the physiological result value is greater than the threshold value, and that a sufficient time interval has elapsed since the previous administration, it sends a signal to the connecting means 5 to allow subsequent administration of said first active formulation 12; or - if the signal processing unit 4 determines that the physiological result value is below the threshold value, or an insufficient time interval has elapsed since the previous administration, it sends a signal to the means of relating to allow subsequent administration of said second active formulation 11.  [000159] In one embodiment, the storage spaces are removable.  [000160] In one embodiment, the storage spaces are interchangeable.  [000161] In one embodiment, the storage spaces 2 and 3 are removable and interchangeable.  Indeed, as previously stated, the medical device 1 incorporates several active formulations whose qualitative and quantitative compositions can be adapted to a given patient.  The choice of this or that dosage, as well as the use of such active principle (s), may be at the discretion of the medical staff.  In addition, the time interval can be predetermined by the medical staff.  In one embodiment, the medical device is further provided with a patient signal device 9.  In one embodiment, the patient signal device 9 consists of a light signal 9a.  With regard to the doses of DR and ADR active ingredients, all doses were estimated for patients of about 70 kg, which represents an average weight.
[0002] These doses may vary, especially when the weight of the patients is different. They can also be adapted according to the animal species. The adaptation of the doses is well known to those skilled in the art. The following embodiments may be applied to the method of administration according to the invention, to the active principles for their use in the treatment of pain, to the delivery system according to the invention and to the portable device according to the invention. invention 1 incorporating such a system. In one embodiment, the measurement of a biological parameter is obtained by means of a device for measuring at least one biological parameter introduced into the nasal cavity concomitantly with each administration. [000168] In one embodiment, the threshold value of the time counting means is between 1 and 10 hours. [000169] In one embodiment, the threshold value of the time counting means is between 4 and 8 hours. In one embodiment, the threshold value of the time counting means is about 6 hours. In one embodiment, the measurement of a biological parameter is selected from the group consisting of oxygen saturation measurement, expired oxygen intranasal level, expired carbon dioxide intranasal rate, and frequency. respiratory. In one embodiment, the measurement of a biological parameter is the measurement of the oxygen saturation. In one embodiment, the threshold value of the measurement of the oxygen saturation is between 70 and 90%. In one embodiment, the threshold value of the oxygen saturation measurement is between 80 and 90%. In one embodiment, the threshold value of the measurement of oxygen saturation is about 85 ° h. In one embodiment, the measurement of a biological parameter is the measurement of the respiratory rate. threshold value of the es / minute. threshold value of the es / minute. threshold value of the [000177] In a respiratory mode is included [000178] In a respiratory mode is included [000179] In a respiratory mode and of embodiment, the between 8 and 14 cycl of realization, the between 8 and 12 cycl of realization, the 12 cycles / minute. In one embodiment, the biological parameters are oxygen saturation and respiratory rate. In one embodiment, the biological parameters are oxygen saturation and respiratory rate. [000181] In one embodiment, the active ingredients are in the form of sprayable liquids. In one embodiment, the at least one active ingredient from the DR group and the at least one active ingredient from the ADR group, when administered simultaneously, are in the form of a mixture. In one embodiment, only one active ingredient from the DR group and an active ingredient from the ADR group are used. In one embodiment, the active ingredients from the DR group used during the initial step and the at least one subsequent step are identical. In one embodiment, the active principles from the DR group used during the initial step and the at least one subsequent step are different. In one embodiment, the active ingredients from the ADR group used during the initial step and the at least one subsequent step are identical. In one embodiment, the active ingredients from the ADR group used during the initial step and the at least one subsequent step are different. In one embodiment, the DR group is constituted by the opioid agonist active ingredients and the ADR group is constituted by the opioid antagonist active principles. In one embodiment, at least one active ingredient of the DR group is selected from the group consisting of alfentanil, anileridine, apomorphine, buprenorphine, butorphanol, carfentanil, codeine, diamorphine. ("Heroin"), dextropropoxyphene, dihydromorphine, fentanyl, hydrocodone, hydromorphone, levallorphan, levophenacylmorphan, levorphanol, methadone, morphine, nalbuphine, nalorphine, norlevophanol, oxycodone , oxymorphone, pentazocine, pethidine, propoxyphene, remifentanil, sufentanil, tramadol, etc. In one embodiment, at least one active ingredient of the DR group is selected from the group consisting of sufentanil, fentanyl, diamorphine, buprenorphine, and carfentanil. [000191] In one embodiment, at least one active ingredient of the DR group is sufentanil. [000192] In one embodiment, at least one active ingredient of the ADR group is selected from the group consisting of naloxone and naltrexone. [000193] In one embodiment, at least one active ingredient of the ADR group is naloxone. In one embodiment, at least one active ingredient in the DR group is sufentanil and the at least one active ingredient in the ADR group is naloxone. In one embodiment, the dose of sufentanil is between 2 and 50 μg and the dose of naloxone is between 2 and 50 mg. In one embodiment, the dose of sufentanil is between 5 and 30 μg and the dose of naloxone is between 5 and 30 mg. [000197] In one embodiment, the dose of sufentanil is between 10 and 20 μg and the dose of naloxone is between 10 and 20 mg. [000198] In one embodiment, the dose of sufentanil is 10 μg and the dose of naloxone is 10 mg. [000199] In one embodiment, the dose of sufentanil is 15 μg and the dose of naloxone is 15 mg. In one embodiment, the dose of sufentanil is 20 μg and the dose of naloxone is 20 mg. In one embodiment, the weight ratio of sufentanil to naloxone is between 0.00004 and 0.025. [000202] In one embodiment, the weight ratio of sufentanil to naloxone is about 0.001. In one embodiment, at least one active ingredient of the DR group is sufentanil and the at least one active ingredient in the ADR group is naloxone, and any administration of sufentanil is accompanied by administration of ketamine. simultaneously. [000204] In one embodiment, sufentanil, naloxone and ketamine are in the form of a mixture. In one embodiment, the dose of sufentanil is between 1 and 60 μg, the dose of ketamine is between 1 and 60 mg, and the dose of naloxone is between 1 and 60 mg. In one embodiment, the dose of sufentanil is between 10 and 55 μg, the dose of ketamine is between 10 and 55 mg, and the dose of naloxone is between 10 and 55 mg. In one embodiment, the dose of sufentanil is between 17 and 50 μg, the dose of ketamine is between 17 and 50 mg, and the dose of naloxone is between 17 and 50 mg. In one embodiment, the dose of sufentanil is 17 μg, the dose of ketamine is 17 mg and the dose of naloxone is 17 mg. In one embodiment, the dose of sufentanil is 37.5 μg, the dose of ketamine is 37.5 mg and the dose of naloxone is 37.5 mg. In one embodiment, the dose of sufentanil is 50 μg, the dose of ketamine is 50 mg and the dose of naloxone is 50 μg. [000211] In one embodiment, the weight ratio of sufentanil to naloxone and the weight ratio of ketamine to naloxone are, respectively, between 0.00034 and 0.0029 and between 0.34 and 2.9. In one embodiment, the weight ratio of sufentanil to naloxone is about 0.001 and the weight ratio of ketamine to naloxone is about 1. In one embodiment, at least an active ingredient of the DR group is fentanyl and the at least one active ingredient in the ADR group is naloxone. In one embodiment, the dose of fentanyl is between 10 and 150 μg and the dose of naloxone is between 2 and 50 mg. In one embodiment, the dose of fentanyl is between 30 and 120 μg and the dose of naloxone is between 5 and 30 mg. In one embodiment, the dose of fentanyl is between 50 and 100 μg and the dose of naloxone is between 10 and 20 mg. In one embodiment, the dose of fentanyl is 50 μg and the dose of naloxone is 10 mg. In one embodiment, the dose of fentanyl is 75 μg and the dose of naloxone is 15 mg. In one embodiment, the dose of fentanyl is 100 μg and the dose of naloxone is 20 mg. In one embodiment, the weight ratio of fentanyl to naloxone is from 0.0002 to 0.075. In one embodiment, the weight ratio of fentanyl to naloxone is about 0.005. In one embodiment, at least one active ingredient in the DR group is diamorphine and the at least one active ingredient in the ADR group is naloxone. In one embodiment, the dose of diamorphine is between 0.1 and 20 mg and the dose of naloxone is between 2 and 50 mg. In one embodiment, the dose of diamorphine is between 1 and 10 mg and the dose of naloxone is between 5 and 10 mg. In one embodiment, the dose of diamorphine is between 2 and 4 mg and the dose of naloxone is between 10 and 20 mg. In one embodiment, the dose of diamorphine is 2 mg and the dose of naloxone is 10 mg. In one embodiment, the dose of diamorphine is 3 mg and the dose of naloxone is 15 mg. In one embodiment, the dose of diamorphine is 4 mg and the dose of naloxone is 20 mg. In one embodiment, the weight ratio between the diamorphine and the naloxone is between 0.02 and 10. In one embodiment, the weight ratio between the diamorphine and the naloxone is about 0. 2. In one embodiment, at least one active ingredient in the DR group is buprenorphine and the at least one active ingredient in the ADR group is naloxone. In one embodiment, the dose of buprenorphine is between 0.1 and 30 mg and the dose of naloxone is between 0.1 and 5 mg. In one embodiment, the dose of buprenorphine is between 1 and 15 mg and the dose of naloxone is between 0.3 and 3 mg. In one embodiment, the dose of buprenorphine is between 2 and 8 mg and the dose of naloxone is between 0.5 and 2 mg. [000235] In one embodiment, the dose of buprenorphine is 2 mg and the dose of naloxone is 0.5 mg. In one embodiment, the dose of buprenorphine is 4 mg and the dose of naloxone is 1 mg. In one embodiment, the dose of buprenorphine is 6 mg and the dose of naloxone is 1.5 mg. In one embodiment, the dose of buprenorphine is 8 mg and the dose of naloxone is 2 mg. In one embodiment, the weight ratio of buprenorphine to naloxone is from 0.02 to 300. In one embodiment, the weight ratio of buprenorphine to naloxone is about 4: 1. In one embodiment, at least one active ingredient in the DR group is carfentanil and the at least one active ingredient in the ADR group is naloxone. In one embodiment, the dose of carfentanil is between 70 and 1900 μg and the dose of naloxone is between 0.3 and 3.7 mg. In one embodiment, the dose of carfentanil is between 140 and 1400 μg and the dose of naloxone is between 0.5 and 3.0 mg. [000244] In one embodiment, the dose of carfentanil is between 350 and 1000 μg and the dose of naloxone is between 0.7 and 2.0 mg. [000245] In one embodiment, the carfentanil dose is 350 μg and the naloxone dose is 0.70 mg. In one embodiment, the dose of carfentanil is 700 μg and the dose of naloxone is 1.4 mg. [000247] In one embodiment, the dose of carfentanil is 1000 μg and the dose of naloxone is 2 mg. In one embodiment, the weight ratio of carfentanil to naloxone is from 0.019 to 6.6. In one embodiment, the weight ratio of carfentanil to naloxone is about 0.5. In one embodiment, in the active formulation comprising no active principle of the DR group, the at least one active ingredient of the ADR group is naloxone and the dose of naloxone is between 1 and 40 mg. In one embodiment, in the active formulation comprising no active principle of the DR group, the at least one active principle of the ADR group is naloxone and the dose of naloxone is between 5 and 20 mg. When the at least one DR active ingredient is buprenorphine, in the active formulation that does not comprise any active principle of the DR group, the at least one active ingredient in the ADR group is naloxone and the dose of naloxone is included. between 3 and 7 mg. In one embodiment, the DR group consists of benzodiazepines and the ADR group consists of benzodiazepine antagonists. [000254] In one embodiment, the benzodiazepines are selected from the group consisting of lorazepam, midazolam and flunitrazepam. [000255] In one embodiment, the benzodiazepine antagonist is flumazenil. [000256] In one embodiment, the benzodiazepine is lorazepam and the benzodiazepine antagonist is flumazenil. In one embodiment, the dose of lorazeparn is between 2 and 5 mg. [000258] In one embodiment, the benzodiazepine is midazolam and the benzodiazepine antagonist is flumazenil. In one embodiment, the dose of midazolam is between 3.5 and 10 mg. [000260] In one embodiment, the benzodiazepine is flunitrazepam and the benzodiazepine antagonist is flumazenil. In one embodiment, the dose of flunitrazepam is between 2 and 10 mg. In one embodiment, in the active formulation comprising no active principle of the DR group, the at least one active principle of the ADR group is flumazenil and the dose of flumazenil is between 0.1 and 1 mg. In one embodiment, in the active formulation comprising no active principle of the DR group, the at least one active principle of the ADR group is flumazenil and the dose of flumazenil is between 0.6 and 1 mg. In one embodiment, the at least one active ingredient from the DR group is selected from benzodiazepines and the active formulation comprising the at least one active ingredient from the DR group does not include an active ingredient of the ADR group. . In one embodiment, the at least one active ingredient from the DR group is lorazepam and the active formulation comprising lorazepam does not include flumazenil. In one embodiment, the at least one active ingredient from the DR group is midazolam and the active formulation comprising midazolam does not include flumazenil. In one embodiment, the at least one active ingredient from the ADR group is flunitrazepam and the active formulation comprising flunitrazepam does not include flumazenil. In one embodiment, the measurement of a biological parameter is obtained by means of a device for measuring at least one biological parameter introduced into the nasal cavity concomitantly with each administration, the threshold value of the average time count is between 4 and 8 hours, the measurements of a biological parameter are oxygen saturation and respiratory rate, the at least one active ingredient from the DR group and the at least one active ingredient derived from the ADR group, when administered simultaneously, are in the form of a mixture, the active ingredient (s) from the DR group used in the initial stage and the at least one subsequent step is identical, the at least one active ingredient of the DR group is sufentanil, the at least one active ingredient of the ADR group is naloxone. The dose of sufentanil is between 17 and 50 μg and the dose of naloxone is between 17 and 50 mg. In one embodiment, the measurement of a biological parameter is obtained by means of a device for measuring at least one biological parameter introduced into the nasal cavity concomitantly with each administration, the threshold value of the average Biological parameter measurements are oxygen saturation and respiratory frequency, the at least one active ingredient from the DR group and the at least one active ingredient from the ADR group, when administered simultaneously. are in the form of a mixture, the active principle (s) resulting from the DR group used during the initial step and the at least one subsequent step are identical, at least one active ingredient of the DR group is sufentanil, the at least one active ingredient of the ADR group is naloxone, the dose of sufentanil is between 17 and 50 μg and the dose of naloxone is between 17 and 50 mg any administration of sufentanil is accompanied by an administration ketamine simultaneously, sufentanil and ketamine are in the form of a mixture, the dose of ketamine is between 17 and 50 mg. In one embodiment, the measurement of a biological parameter is obtained by means of a device for measuring at least one biological parameter introduced into the nasal cavity concomitantly with each administration, the threshold value of the average time count is between 4 and 8 hours, the measurements of a biological parameter are oxygen saturation and respiratory rate, the at least one active ingredient from the DR group and the at least one active ingredient derived from the ADR group, when administered simultaneously, are in the form of a mixture, the active ingredient (s) from the DR group used in the initial stage and the at least one subsequent step is identical, the at least one active principle of the DR group is fentanyl, the at least one active ingredient of the ADR group is naloxone, the fentanyl dose is between 50 and 100 μg, and the dose of naloxone is between 10 and 20 mg. In one embodiment, the measurement of a biological parameter is obtained by means of a device for measuring at least one biological parameter introduced into the nasal cavity concomitantly with each administration, the threshold value of the average time count is between 4 and 8 hours, the measurements of a biological parameter are oxygen saturation and respiratory rate, the at least one active ingredient from the DR group and the at least one active ingredient derived from the ADR group, when administered simultaneously, are in the form of a mixture, the active ingredient (s) from the DR group used in the initial stage and the at least one subsequent step is identical, the at least one active principle of the DR group is diamorphine, the at least one active ingredient of the ADR group is naloxone, the dose of diamorphine is between 2 and 4 mg and the dose of naloxone is between 10 and 20 mg. In one embodiment, the measurement of a biological parameter is obtained by means of a device for measuring at least one biological parameter I introduced into the nasal cavity concomitantly with each administration, the threshold value of time counting means is between 4 and 8 hours, the measurements of a biological parameter are the oxygen saturation and respiratory rate, the at least one active ingredient from the DR group and the at least one principle ADR group, when administered simultaneously, are in the form of a mixture, the active principle (s) from the DR group used during the step initial and at least one subsequent step are identical, the at least one active ingredient of the DR group is buprenorphine, the at least one active ingredient of the ADR group is naloxone, the buprenorphine dose is between 2 and 8 mg and the dose of naloxone is between 0.5 and 2 mg. In one embodiment, the measurement of a biological parameter is obtained by means of a device for measuring at least one biological parameter introduced into the nasal cavity concomitantly with each administration, the threshold value of the average time count is between 4 and 8 hours, the measurements of a biological parameter are oxygen saturation and respiratory rate, the at least one active ingredient from the DR group and the at least one active ingredient derived from the ADR group, when administered simultaneously, are in the form of a mixture, the active ingredient (s) from the DR group used in the initial stage and the at least one subsequent step is identical, the at least one active principle of the DR group is carfentanil, the at least one active ingredient of the ADR group is naloxone, the dose of carfentanil is between 350 and 1000 μg and the dose of naloxone is between 0.7 and 2.0 mg. In one embodiment, the measurement of a biological parameter is obtained by means of a device for measuring at least one biological parameter introduced into the nasal cavity concomitantly with each administration, the threshold value of the average time measurement is between 4 and 8 hours, the measurements of a biological parameter are the oxygen saturation and the respiratory rate, the active principle (s) resulting from the DR group used ( s) during the initial stage and the at least one subsequent stage are identical, the at least one active principle of the DR group is midazolam, the dose of midazolam is between 3.5 and 10 mg, in the active formulation does not include active principle of the DR group, the at least one active ingredient of the ADR group is flumazenil and the dose of flumazenil is between 0.6 and 1 mg. In one embodiment, the measurement of a biological parameter is obtained by means of a device for measuring at least one biological parameter introduced into the nasal cavity concomitantly with each administration, the threshold value of the average time measurement is between 4 and 8 hours, the measurements of a biological parameter are the oxygen saturation and the respiratory rate, the active principle (s) resulting from the DR group used ( s) during the initial step 3032353 and the at least one subsequent step are identical, the at least one active principle of the DR group is lorazepam, the dose of lorazepam is between 2 and 5 mg, in the formulation active ingredient does not comprise active principle of the DR group, the at least one active principle of the ADR group is flumazenil and the dose of flumazenil is between 0.6 and 1 mg. In one embodiment, the measurement of a biological parameter is obtained by means of a device for measuring at least one biological parameter introduced into the nasal cavity concomitantly with each administration, the threshold value of the average time measurement is between 4 and 8 hours, the measurements of a biological parameter are the oxygen saturation and the respiratory rate, the active principle (s) resulting from the DR group used ( s) during the initial stage and the at least one subsequent stage are identical, the at least one active principle of the DR group is flunitrazepam, the dose of flunitrazepam is between 2 and 10 mg, in the active formulation comprising no active principle of the DR group, the at least one active principle of the ADR group is flumazenil and the dose of flumazenil is between 0.6 and 1 mg. In one embodiment, at least one of the active formulations comprises at least one pharmaceutical active ingredient in a form that modifies its membrane passage and bioavailability properties. EXAMPLE [000278] This example illustrates an example of use of a medical device 1 according to the invention. [000279] Technical characteristics of the device two removable storage spaces; a first storage space 2 comprising a first active formulation 12: Active formulation 12 (10 mL) in the form of a sufentanil solution 1875 μg ketamine 1875 mg naloxone 1875 mg water and / or excipients (qs 100%) 3032353 [000280] the amount of formulation used at each dose is 0.2 ml, so this active formulation 12 comprises about 50 doses such as: sufentanil (37.5 pg / dose) / ketannine (37.5 mg / dose) / naloxone (37.5 mg / dose). a second storage space 3 comprising an active formulation 11: Active formulation 11 (10 mL) in the form of naloxone solution 750 mg water and / or MSP excipients 100%) The amount of formulation used at each dose is 0.2 ml therefore, this active formulation 11 comprises about 50 doses such as: naloxone (15 ng / dose). two devices measuring biological parameters: an oxygen sensor 6c (measuring the oxygen saturation, threshold value 85%) and a respiratory rate sensor 6b (threshold value: 12 inhalation / exhalation cycles per minute); a time counting device: a clock 6a (threshold value: 6 hours); a patient signaling device 9: when one of the threshold values of the oximeter 6c or the respiratory rate sensor 6b or the threshold value of the clock 6a is against a re-administration of sufentanil, the indicator light 9a lights up on the device 1. From then on, the patient knows what will be administered to him in case of activation of the control means 8. He may make a decision: activate the control means 8 or not. [000282] Course of the therapy [000283] At T = 0, the patient, apart from any medicalized structure, actuates for the first time the control means 8 of the device 1: it is administered the active formulation 12. [000284 At T = 3 hours, he introduces the nosepiece 7a of the device 1 into one of his nostrils. After about 20 seconds, the indicator light 9a lights up, indicating that the clock (and potentially its biological parameters) prohibits (prohibit) the administration of the active formulation 12: it has the choice to administer itself the active formulation 11 or not being administered. At T = 6.1 hours, he introduces the tip of the device into one of his nostrils. After about 20 seconds, the indicator light 9a illuminates, indicating that at least one of its two biological parameters prohibits the administration of the active formulation 12: it has the choice to administer the active formulation 11 or not to administer anything. At T = 8 hours, he introduces the tip of the device into one of his nostrils. After about 20 seconds, the indicator light 9a remains off: it can administer the active formulation 12.

权利要求:
Claims (8)
[0001]
REVENDICATIONS1. Intranasal sequential administration system of at least one active principle belonging to the group of active principles having at least one respiratory depressant side effect DR and of at least one active principle belonging to the group of active principles that counteract the respiratory depression ADR that can be induced by the active ingredients of the DR group, which system comprises: (a) the administration of at least one active ingredient from the DR group, in response to an initial actuation of the system by a subject wishing to receive the pharmaceutical administration, this administration constituting an initial administration registered by the system; (b) at least one administration subsequent to the initial administration, either of at least one active ingredient from the ADR group, or of at least one active ingredient from the DR group, in response to at least one subsequent actuation of the system performed by a subject desiring to receive subsequent pharmaceutical administration, which administration constitutes a subsequent event recorded by the system; the choice of the subsequent administration being dependent on one or more means of intelligence.
[0002]
An intranasal sequential delivery system according to claim 1, which system comprises: (a) simultaneous administration of at least one active ingredient from the DR group and from at least one active ingredient from the ADR group, in response an initial actuation of the system by a subject desiring to receive the pharmaceutical administration, said administration constituting an initial administration recorded by the system; (b) at least one administration subsequent to the initial administration, either of at least one active ingredient from the ADR group, or at least one active ingredient from the DR group and from at least one active ingredient from the group ADR simultaneously, in response to at least one subsequent actuation of the system performed by a subject desiring subsequent pharmaceutical administration, which administration constitutes a subsequent event recorded by the system; the choice of the subsequent administration being dependent on one or more means of intelligence. 3032353 39
[0003]
A portable intranasal sequential administration medical device (1) incorporating a sequential intranasal delivery system according to any one of the preceding claims 1 to 2.
[0004]
An intranasal sequential administration medical device (1) according to claim 3, which comprises: a first storage space (2) containing a first sprayable active formulation (12) comprising at least one active ingredient from the DR group (12a) ); a second storage space (3) comprising a second sprayable active formulation (11) different from the first active formulation and comprising at least one active ingredient from the ADR group (11a); a signal processing unit (4); means for relating (5) the first (12) and second (11) active formulations of said first (2) and second (3) respective storage spaces with the dispensing means (7) operably connected to the signal processing unit (4); at least one or more intelligence means (6), operatively connected to the signal processing unit (4); control means (8) enabling the subject receiving said active formulations to perform self-administration of said active formulations outside of any medicalized structure; - Distribution means (7) of the active formulations adapted for transmission through the nasal mucosa; and an autonomous energy source (10), the signal processing unit (4), the linking means (5), the intelligence means (s) (6) and the control means (8) being configured to allow, as a function of one or more signals received by the signal processing unit (4) from the at least one intelligence means (6), either linking the first active formulation (12) of the first storage space (2) to the distribution means (7), ie the linking of the second active formulation (11) of the second storage space (3) to the distribution means (7) .
[0005]
5. Device according to claim 4, wherein the at least one active principle of the DR group is selected from the group consisting of benzodiazepines and the at least one active ingredient of the ADR group is flumazenil. 3032353 40
[0006]
A portable intranasal sequential administration medical device (1) according to any one of claims 3 to 4 which comprises: a first storage space (2) containing a first sprayable active formulation (12) comprising at least one active ingredient derived from of the DR group (12a) and at least one active ingredient from the ADR group (12b) a second storage space (3) comprising a second active formulation (11) sprayable different from the first active formulation and comprising at least one active ingredient derived from ADR group (11a); a signal processing unit (4); means for relating (5) the first (12) and second (11) active formulations of said first (2) and second (3) respective storage spaces with the dispensing means (7) operably connected to the signal processing unit (4); at least one or more intelligence means (6), operatively connected to the signal processing unit (4); control means (8) allowing the subject to receive said active formulations to self-administer said active formulations outside any medical facility; - Distribution means (7) of the active formulations adapted for transmission through the nasal mucosa; and an autonomous energy source (10), the signal processing unit (4), the linking means (5), the intelligence means (s) (6) and the control means (8) being configured to allow, as a function of one or more signals received by the signal processing unit (4) from the at least one intelligence means (6), either linking the first active formulation (12) of the first storage space (2) to the distribution means (7), ie the linking of the second active formulation (11) of the second storage space (3) to the distribution means (7) .
[0007]
7. Device according to claim 6, wherein the at least one active ingredient of the DR group is sufentanil and the at least one active ingredient in the ADR group is nalokone.
[0008]
8. Device according to any one of claims 3 to 7, wherein the intelligence means are at least one device for measuring at least one biological parameter and a time counting means.

类似技术:

---

公开号 | 公开日 | 专利标题

---

FR3032353A1|2016-08-12|PHARMACEUTICAL COMPOSITION AND DEVICE FOR THE TREATMENT OF PAIN

---

Sivilotti2016|Flumazenil, naloxone and the ‘coma cocktail’

---

AU724993B2|2000-10-05|Smoking cessation treatments using naltrexone and related compounds

---

Ciccocioppo et al.2007|Buprenorphine reduces alcohol drinking through activation of the nociceptin/orphanin FQ-NOP receptor system

---

US20180110939A1|2018-04-26|Method, system and apparatus for controlled delivery of opioid and other medications

---

Henningfield et al.2009|Tobacco dependence and withdrawal: science base, challenges and opportunities for pharmacotherapy

---

Shahab et al.2013|Novel delivery systems for nicotine replacement therapy as an aid to smoking cessation and for harm reduction: rationale, and evidence for advantages over existing systems

---

Lê et al.2014|Operant self-administration of alcohol and nicotine in a preclinical model of co-abuse

---

CA2353364A1|2002-02-03|Aerosol for the treatment or prevention of pain

---

Roche et al.2016|Current insights into the mechanisms and development of treatments for heavy-drinking cigarette smokers

---

Tomek et al.2018|Social influences in animal models of opiate addiction

---

Frick et al.2010|Long-term follow-up of orally administered diacetylmorphine substitution treatment

---

Ward et al.2018|Effects of pharmacological manipulation of the kappa opioid receptors on the aversive effects of nicotine

---

Jain et al.2021|Tobacco Smoking and Liver Cancer Risk: Potential Avenues for Carcinogenesis

---

Bateman2012|Opioids

---

Nutt2010|Antagonist—agonist combinations as therapies for heroin addiction: back to the future?

---

Waters2021|Pharmacologic Similarities and Differences Among Hallucinogens

---

FR2954699A1|2011-07-01|PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF ALCOHOL DEPENDENCE

---

WO2019091870A1|2019-05-16|Stimulant abuse-deterrent compositions

---

TW200402297A|2004-02-16|Medicament and process for reducing alcohol and/or tobacco consumption

---

Krishnan-Sarin et al.2007|Opioid antagonists for the treatment of nicotine dependence

---

EP3934512A1|2022-01-12|Composition for measuring medication compliance and method thereof

---

Philpott2014|NRT: Quit smoking

---

US20160143974A1|2016-05-26|Vaporized Medicants and Methods of Use

---

McDonald2005|Suboxone: A welcome addition but no silver bullet

同族专利:

---

公开号 | 公开日

---

CN107438447A|2017-12-05|

---

US10406300B2|2019-09-10|

---

JP2018506405A|2018-03-08|

---

WO2016124788A1|2016-08-11|

---

FR3032353B1|2017-03-10|

---

EP3253415A1|2017-12-13|

---

US20160354558A1|2016-12-08|

---

US20170100333A1|2017-04-13|

---

US10406299B2|2019-09-10|

---

CA2975950A1|2016-08-11|

引用文献:

---

公开号 | 申请日 | 公开日 | 申请人 | 专利标题

---

US5512578A|1992-09-21|1996-04-30|Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University|Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by exogenous and endogenous opiod agonists|

---

US6605060B1|1995-06-07|2003-08-12|O'neil Alexander George Brian|Patient controlled drug delivery device|

---

US20140099369A1|2000-02-08|2014-04-10|Purdue Pharma L.P.|Tamper-resistant oral opioid agonist formulations|

---

US6948492B2|2000-08-15|2005-09-27|University Of Kentucky Research Foundation|Programmable multi-dose intranasal drug delivery device|

---

US20070186923A1|2006-01-06|2007-08-16|Aceirx Pharmaceuticals, Inc.|Drug storage and dispensing devices and systems comprising the same|

---

CN102068697A|2010-12-30|2011-05-25|宜昌人福药业有限责任公司|Opiates painkiller and opiate receptor antagonist-containing medicinal composition|US11206872B2|2020-04-07|2021-12-28|Consumernext Labs Gmbh|Stable-foam dispensing device and cartridge|US4464378A|1981-04-28|1984-08-07|University Of Kentucky Research Foundation|Method of administering narcotic antagonists and analgesics and novel dosage forms containing same|

---

FR2610602B1|1987-02-09|1989-07-21|Sofab Ste Fse Aerosol Bouchage|DISPENSING MIXER PACKAGING|

---

GB8726062D0|1987-11-06|1987-12-09|Plaspharm Uk Ltd|Fluid dispensing devices|

---

US5767215A|1991-05-09|1998-06-16|Borealis Holding A/S|Coarse-grained polyolefin, its production method and a catalyst used in the method|

---

GB9202464D0|1992-02-05|1992-03-18|Danbiosyst Uk|Composition for nasal administration|

---

US5580876A|1992-09-21|1996-12-03|Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University|Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other bimodally-acting opioid agonists|

---

US6098620A|1993-01-29|2000-08-08|Aradigm Corporation|Device for aerosolizing narcotics|

---

US5535950A|1994-12-07|1996-07-16|Calmar Inc.|Dual trigger sprayer|

---

US7335186B2|1998-03-13|2008-02-26|Alexander George Brian O'Neil|Patient controlled drug delivery device|

---

US20040115133A1|2000-05-10|2004-06-17|Wermeling Daniel P.|Intranasal opioid compositions|

---

US20040176359A1|2001-02-20|2004-09-09|University Of Kentucky Research Foundation|Intranasal Benzodiazepine compositions|

---

AU6299201A|2000-05-10|2002-02-18|Univ Kentucky Res Found|System and method for intranasal administration of opioids|

---

US6610271B2|2000-05-10|2003-08-26|University Of Kentucky Research Foundation|System and method for intranasal administration of lorazepam|

---

US7931022B2|2001-10-19|2011-04-26|Respirks, Inc.|Method and apparatus for dispensing inhalator medicament|

---

US20030191147A1|2002-04-09|2003-10-09|Barry Sherman|Opioid antagonist compositions and dosage forms|

---

US7681572B2|2002-08-20|2010-03-23|Aga Ab|Method and devices for administration of therapeutic gases|

---

US7337776B2|2002-08-20|2008-03-04|Aga Ab|Methods for easing pain and anxiety from atrial or ventricular defibrillation|

---

US6886557B2|2002-10-31|2005-05-03|Hewlett-Packard Development Company, L.P.|Inhalation device and method for delivering variable amounts of different components|

---

CA2551127A1|2003-12-15|2005-07-07|Alexza Pharmaceuticals, Inc.|Treatment of breakthrough pain by drug aerosol inhalation|

---

US8353896B2|2004-04-19|2013-01-15|The Invention Science Fund I, Llc|Controllable release nasal system|

---

US7512042B2|2004-07-16|2009-03-31|Sanyo Electric Co., Ltd.|Method of controlling focus of optical disk recording and reproducing device|

---

US7827983B2|2004-12-20|2010-11-09|Hewlett-Packard Development Company, L.P.|Method for making a pharmaceutically active ingredient abuse-prevention device|

---

US20060207596A1|2005-03-18|2006-09-21|Fairfield Clinical Trials, Llc|Device and method for delivery of combination nasal medication|

---

US7855196B2|2005-08-22|2010-12-21|Pierre Mainville|Composition comprising a benzodiazepine agonist and a benzodiazepine antagonist|

---

US8865743B2|2006-01-06|2014-10-21|Acelrx Pharmaceuticals, Inc.|Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain|

---

US8753308B2|2006-01-06|2014-06-17|Acelrx Pharmaceuticals, Inc.|Methods for administering small volume oral transmucosal dosage forms using a dispensing device|

---

DE202006018609U1|2006-08-29|2007-05-16|Euro-Celtique S.A.|Needle-free apparatus for administrating pharmaceutical composition in humans, comprises a housing; auxiliary substance to force a pharmaceutical composition from a package into human body; a composition comprising analgesic, e.g. opioids|

---

US8153261B2|2006-09-01|2012-04-10|Momentive Performance Materials Inc.|Solid polymeric substrate having adherent resin component derived from curable silylated polyurethane composition|

---

JP2010529894A|2007-06-15|2010-09-02|スパンドーファー，マイケル|Drug delivery and monitoring system for ventilators|

---

EP2604257B1|2007-08-07|2017-06-28|Acelrx Pharmaceuticals, Inc.|Oral transmucosal dosage forms comprising sufentanil and triazolam|

---

US7875001B2|2008-02-25|2011-01-25|Americo Michael Minotti|Multi medication nasal spray device and method|

---

AU2009223153A1|2008-03-12|2009-09-17|Emory University|Use of GABAa receptor antagonists for the treatment of excessive sleepiness and disorders associated with excessive sleepiness|

---

US8922194B2|2009-09-11|2014-12-30|Alstom Technology Ltd|Master-slave fiber optic current sensors for differential protection schemes|

---

TWI421088B|2009-12-10|2014-01-01|Chen Yu Lee|Use of extract of chinese medical composition for preparing drug for inhibiting growth of lung cancer cells|

---

EP2605698B1|2010-08-17|2020-04-15|University of Florida Research Foundation, Inc.|Central site photoplethysmography, medication administration, and safety|

---

US20130172759A1|2011-08-08|2013-07-04|Richard J. Melker|Systems And Methods For Using Photoplethysmography In The Administration Of Narcotic Reversal Agents|

---

GB201113606D0|2011-08-05|2011-09-21|Norbrook Lab Ltd|Dual chamber syringe|

---

US9486600B2|2013-06-28|2016-11-08|L'Air Liquide, Société Anonyme pour l'Etude et l'Exploitation des Procédés Georges Claude|Nasal cannula assembly with inhalation valves communicating with a deformable reservoir|

---

FR3032353B1|2015-02-06|2017-03-10|Jacques Seguin|PHARMACEUTICAL COMPOSITION AND DEVICE FOR THE TREATMENT OF PAIN|FR3032353B1|2015-02-06|2017-03-10|Jacques Seguin|PHARMACEUTICAL COMPOSITION AND DEVICE FOR THE TREATMENT OF PAIN|

---

US10207064B2|2017-07-11|2019-02-19|Glen McCants|Dual chamber nebulizer apparatus|

---

JP2022507422A|2018-11-16|2022-01-18|ヘクソ・オペレーションズ・インコーポレイテッド|Equipment and methods for multi-chamber, multi-atomizer vaporization devices|

---

WO2021158736A1|2020-02-06|2021-08-12|Corbett Lair, Inc.|Method, apparatus and kit for treating chronic and long-term nasal congestion|

---

US10994083B1|2020-10-02|2021-05-04|Bahram Kam Habibi|Electronic inhaler|

法律状态:
2016-02-21| PLFP| Fee payment|Year of fee payment: 2 |

---

2016-08-12| PLSC| Search report ready|Effective date: 20160812 |

---

2017-01-24| PLFP| Fee payment|Year of fee payment: 3 |

---

2018-01-23| PLFP| Fee payment|Year of fee payment: 4 |

---

2018-08-03| TP| Transmission of property|Owner name: VAPOMED LIMITED, BS Effective date: 20180702 |

---

2018-08-03| TQ| Partial transmission of property|Owner name: VAPOMED LIMITED, BS Effective date: 20180702 |

---

2019-10-25| ST| Notification of lapse|Effective date: 20191006 |

优先权:

---

申请号 | 申请日 | 专利标题

---

FR1550985A|FR3032353B1|2015-02-06|2015-02-06|PHARMACEUTICAL COMPOSITION AND DEVICE FOR THE TREATMENT OF PAIN|FR1550985A| FR3032353B1|2015-02-06|2015-02-06|PHARMACEUTICAL COMPOSITION AND DEVICE FOR THE TREATMENT OF PAIN|

---

US15/120,120| US10406299B2|2015-02-06|2016-02-08|Pharmaceutical composition and device for treating pain|

---

CN201680020532.9A| CN107438447A|2015-02-06|2016-02-08|For treating the pharmaceutical composition and device of pain|

---

EP16705065.7A| EP3253415A1|2015-02-06|2016-02-08|Pharmaceutical composition and device for treating pain|

---

JP2017559910A| JP2018506405A|2015-02-06|2016-02-08|Pharmaceutical composition and device for pain treatment|

---

PCT/EP2016/052640| WO2016124788A1|2015-02-06|2016-02-08|Pharmaceutical composition and device for treating pain|

---

CA2975950A| CA2975950A1|2015-02-06|2016-02-08|Pharmaceutical composition and device for treating pain|

---

US15/241,030| US10406300B2|2015-02-06|2016-08-18|Dual chamber inhaler for sequentially administering multiple drugs|